Marco Meglio

Recently published study links white matter changes to cognitive decline, emphasizing the cingulum and fornix as key biomarkers for memory loss.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the use of lithium to treat Alzheimer disease.

A recent study reassured that triptans may be safe for migraine treatment, emphasizing the need for individualized assessments of cardiovascular risks.

A new study reveals rituximab outperforms cladribine in managing MRI disease activity in relapsing multiple sclerosis over 4.5 years.

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

New study reveals vormatrigine significantly reduces focal onset seizures, offering hope for improved epilepsy treatments at the upcoming International Epilepsy Congress.

The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer, urging further research for validation.

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on orexin receptor agonists.

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alexa Dessy, MD. [LISTEN TIME: 17 minutes]

Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

The neurologist at Duke Health provided insights on how chronic demyelinating inflammatory polyneuropathy treatment is evolving toward biomarker-driven, personalized approaches at the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 2 minutes]

Teva's fremanezumab gains FDA approval for pediatric migraine prevention, offering a vital treatment option for children aged 6-17.

The chief scientific officer at Alzheon discussed the mechanism of valiltramiprosate and new data on toxic amyloid oligomers presented at the recently concluded Alzheimer’s Association International Conference.

New findings reveal the promising efficacy and safety of a subcutaneous lecanemab autoinjector for early Alzheimer disease treatment, enhancing patient care.

A real-world study reveals lecanemab's effectiveness in early Alzheimer's, showing stability or improvement in 83.6% of patients after two years.

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.

A groundbreaking phase 2 study evaluates PRI-002's potential to treat mild Alzheimer's symptoms, aiming for significant safety and efficacy insights by 2026.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on anti-amyloid treatments for Alzheimer disease.

Valiltramiprosate shows promising effects on brain structure and cognitive function in early Alzheimer disease, highlighting its potential for MCI treatment.

Roche's Elecsys pTau181 blood test gains CE Mark, enhancing early Alzheimer’s diagnosis and improving patient outcomes across the European Union.